Stock Price Forecast

March 14, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Repligen Corp. chart...

About the Company

repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.

CEO

Anthony Hunt

Exchange

NASDAQ

Website

https://www.repligen.com/

$44M

Total Revenue

1K

Employees

$11B

Market Capitalization

122.57

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $RGEN News

Are Repligen Corporation's (NASDAQ:RGEN) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

14h ago, source:

Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors’ money. In simpler terms, it measures the profitability of a company in relation to ...

Repligen Corp CEO Anthony Hunt Sells 16,707 Shares

6d ago, source: Yahoo Finance

Repligen Corp (NASDAQ:RGEN), a bioprocessing company focused on the development, manufacture, and commercialization of products used in the process of drug manufacturing, has reported an insider sale ...

What's Going On With Life Science-Focused Repligen Stock Today?

26d ago, source: Hosted on MSN

Repligen Corporation (NASDAQ:RGEN) reported fourth-quarter 2023 adjusted EPS of $0.33, in line with the consensus estimate. The life science company reported sales of $155.74 million, down from $ ...

Repligen (RGEN) Price Target Increased by 8.15% to 203.98

23d ago, source: Hosted on MSN

Repligen Background Information (This description is provided by the company.) Repligen Corporation is a global life sciences company that develops and commercializes highly innovative ...

Repligen Corporation (RGEN) Q4 2023 Earnings Call Transcript

26d ago, source: Seeking Alpha

Good day, ladies and gentlemen, and welcome to Repligen Corporation's Fourth Quarter of 2023 Earnings Conference Call. My name is Sabrina, and I will be your coordinator. [Operator Instructions].

Repligen Corp RGN

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Repligen: Q4 Earnings Snapshot

27d ago, source: SFGate

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Repligen Corp. (RGEN) on Wednesday reported a loss of $25.5 million in its fourth quarter. The Waltham, Massachusetts-based company said it had a ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...